MedTrace Logo

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-04-07

No results posted yet for this study

Summary

The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic medication levetiracetam (LEV) normalizes these measures and improves cognition.

Conditions

Interventions

DRUG

Levetiracetam

Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability

DRUG

Placebo oral capsule

The placebo is a capsule that is identical in appearance to the levetiracetam

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-22
Primary Completion
2026-02-16
Completion
2026-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875638 on ClinicalTrials.gov